-

Viz.ai Named to Forbes AI 50 List of Top Artificial Intelligence Companies of 2023

Only company in healthcare to be recognized for the fourth time

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced it has been named to the 2023 Forbes AI 50 list of the most promising private artificial intelligence (AI) startups globally. This is the 4th time Viz.ai has been recognized in the Forbes AI 50 list.

“We are honored to be included in this year’s Forbes AI 50 list and proud that the Viz Platform is recognized globally for its unique value,” said Chris Mansi, CEO at Viz.ai. “By harnessing the power of AI, our platform addresses healthcare’s most pressing needs, helping to accelerate patient care by reducing systemic delays that stand between life-saving treatments and the individuals who need them.”

The Forbes AI 50 list is a preeminent recognition acknowledging the most transformative companies utilizing AI technology for the betterment of the business industry. In prior years, submissions were open to North America alone, but for the first time this year, the criteria was expanded to include startups globally with nearly 800 submissions in 2023.

The Viz Platform uses AI to detect disease earlier, unify care collaboration, and inform critical decisions to improve patient outcomes. Based on a patient’s suspected condition, the Viz Platform automatically alerts the care team to expedite a diagnosis and accelerate initiation of appropriate monitoring and treatment. Throughout the entire clinical workflow, from pre-hospital to post-acute care, healthcare providers can directly connect and assess high fidelity imaging and patient information in real-time. The Viz Platform offerings span neurology, vascular, cardiology, radiology and trauma.

To determine which companies that will be recognized on the AI 50 list, Forbes, in partnership with Sequoia Capital and Meritech Capital, commissions a panel of independent judges with deep expertise in the field of AI to assess notable determinants of each contender including, revenue, growth, valuation, talent on staff, and the strength of the company’s AI business application.

About Viz.ai, Inc.

Viz.ai is the pioneer in the use of AI algorithms and machine learning to increase the speed of diagnosis and care, covering more than 220 million lives across 1,300+ hospitals and health systems in the U.S. and Europe. The AI-powered Viz Platform is an intelligent care coordination solution that identifies more patients with a particular disease, informs critical decisions at the point of care, and optimizes care pathways and helps improve outcomes. Backed by real-world clinical evidence, the Viz Platform delivers significant value to patients, providers, and pharmaceutical and medical device companies. For more information visit viz.ai.

Contacts

More News From Viz.ai, Inc.

New Data Show Viz.ai’s AI-Enabled ECG Screening Increases Detection and Accelerates Diagnosis of Hypertrophic Cardiomyopathy

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced new clinical data demonstrating how Viz HCM enables faster, accurate detection of hypertrophic cardiomyopathy (HCM), to help ensure that more patients are identified. Two studies, which will be presented at the American Heart Association (AHA) Scientific Sessions 2025, show Viz.ai’s real-world ability to identify more patients with HCM years earlier than current...

Viz.ai Launches Viz Assist: The First Multimodal AI Agent Platform for Faster Treatment and Better Outcomes

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced the launch of Viz Assist™, a suite of autonomous AI agents that significantly enhance how care teams identify, prioritize, and act on critical patient data.1 Viz Assist marks a major step forward in Viz.ai’s mission to use technology to reduce time to treatment and improve patient outcomes. Viz Assist incorporates inputs from ambient listening and the electronic...

Viz.ai Launches Viz ACS™ to Accelerate Treatment for Heart Attack and Reduce Unnecessary Activations

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced the launch of Viz ACS, a new solution in the Viz Cardio™ Suite. Designed to unite the acute coronary syndrome (ACS) care team on a single platform, Viz ACS provides Emergency Department (ED) physicians and cardiologists with the same high-quality ECGs and patient data in real time. This streamlined workflow can help improve communication, speeds treatment, and re...
Back to Newsroom